cyclophosphamide + IMA901 + sargramostim

This drug combination consists of **cyclophosphamide** (an alkylating chemotherapy agent), **IMA901** (a multi-peptide therapeutic cancer vaccine made from naturally presented tumor-associated peptides), and **sargramostim** (a recombinant human granulocyte-macrophage colony-stimulating factor, GM-CSF). The regimen is designed for the treatment of advanced or metastatic renal cell carcinoma, aiming to optimize immune response: cyclophosphamide reduces regulatory T cells (Tregs) that suppress immune function; IMA901 stimulates antigen-specific T-cell responses against tumor antigens; sargramostim serves as an immunomodulator that stimulates production and activation of dendritic cells and other white blood cells, enhancing antigen presentation and immunity. In clinical studies, administration of this combination resulted in robust, multi-peptide-specific T-cell responses linked to improved disease control and overall survival in renal cell carcinoma patients[1][3][5][7].

Other names

GM-CSF